Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report report published on Friday morning,RTT News reports. They currently have a $83.00 price objective on the stock.
IRON has been the topic of several other reports. Stifel Nicolaus lifted their target price on shares of Disc Medicine from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. Scotiabank lifted their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a research report on Tuesday, November 5th. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Finally, Jefferies Financial Group initiated coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price on the stock. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Disc Medicine presently has an average rating of “Buy” and a consensus target price of $87.50.
Get Our Latest Report on Disc Medicine
Disc Medicine Price Performance
Disc Medicine (NASDAQ:IRON – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15. On average, analysts anticipate that Disc Medicine will post -4.05 earnings per share for the current year.
Insider Transactions at Disc Medicine
In other news, Director William Richard White sold 1,957 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $64.63, for a total value of $126,480.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John D. Quisel sold 19,820 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $63.14, for a total transaction of $1,251,434.80. Following the completion of the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,550,184.10. The trade was a 21.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 85,758 shares of company stock worth $5,400,990. 4.24% of the stock is owned by insiders.
Hedge Funds Weigh In On Disc Medicine
Several large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in Disc Medicine by 16.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock valued at $799,000 after purchasing an additional 2,257 shares during the last quarter. Exome Asset Management LLC raised its stake in Disc Medicine by 5.8% during the 3rd quarter. Exome Asset Management LLC now owns 64,516 shares of the company’s stock valued at $3,170,000 after purchasing an additional 3,516 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in Disc Medicine by 38.7% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company’s stock valued at $961,000 after purchasing an additional 5,458 shares during the last quarter. Geode Capital Management LLC raised its stake in Disc Medicine by 17.6% during the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock valued at $23,333,000 after purchasing an additional 70,983 shares during the last quarter. Finally, Barclays PLC raised its stake in Disc Medicine by 123.7% during the 3rd quarter. Barclays PLC now owns 40,145 shares of the company’s stock valued at $1,972,000 after purchasing an additional 22,202 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.
About Disc Medicine
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Read More
- Five stocks we like better than Disc Medicine
- What Are Dividend Champions? How to Invest in the Champions
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Quiet Period Expirations Explained
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.